PlainPill

MK-677 vs Retatrutide for appetite

Short answer: For appetite, more users report improvement with Retatrutide — 73% of 86 reports, versus 66% of 228 for MK-677.

MK-677 has 0 meta-analyses and 15 randomized trials on PubMed; Retatrutide has 22 and 6.

Based on 978 reports about MK-677 and 460 about Retatrutide. Not medical advice.

MK-677
Substance
Retatrutide
Peptide
Users say it helped39%helped479 reports · high confidence76%helped327 reports · high confidence
Verdict
Mixed
Mostly positive
ResearchBResearch: ModerateBResearch: Moderate
Meta-analyses / RCTs0 / 1522 / 6
Mainly used for
Appetite
% reporting improvement
66% (228)73% (86)
Weight loss
% reporting improvement
53% (55)92% (228)
Sleep
% reporting improvement
79% (170)31% (26)
Energy
% reporting improvement
37% (62)69% (75)
Performance
% reporting improvement
90% (87)82% (33)
Common side effectswater retention, fatigue, stomach issues, hungernausea, fatigue, stomach issues, insomnia
Typical dose reported12.5 mg / before dinnerNot listed
MK-677
What a user said
“From my own experience (also have suffered from poor sleep), i experienced a noticeable increase in sleep quality even with a low dose.”
Full MK-677 profile →
Retatrutide
Latest review conclusion

This systematic review identifies the state and mechanism of action of emerging pharmacotherapies undergoing or having completed phase 2 and phase 3 clinical trials. The information provided herein furthers the understanding of obesity management, implying direct clinical implications and stimulating research initiatives.

Pharmacol Rev, 2025 ↗
What a user said
“Drastically reduced appetite: At 5mg, I experienced near-total suppression of hunger and cravings. Steady, effortless fat loss: I didn't have to track macros obsessively or do extreme cardio.”
Full Retatrutide profile →

Related comparisons

Percentages come from first-hand user reports and are not clinical outcomes. Talk to a doctor before starting, stopping or combining anything. How we rate